Historically, oropharyngeal cancer (OPC) has been attributed to risk factors such as smoking and alcohol use. The increased incidence of OPC has been driven by human papillomavirus (HPV) infection.
Methods
A search of the literature involving HPV infection and OPC was performed, along with a search of ongoing clinical trials regarding HPV-positive OPC.
Results
This review summarizes the differences in epidemiology and prognosis of HPV-positive OPC compared with non–HPV-related OPC. It will also discuss use of de-escalating treatment to minimize toxicity while maintaining excellent outcomes. Disease management is also addressed, including prevention and follow-up recommendations for this cohort of patients.
Conclusions
HPV-positive OPC is a distinct disease, and efforts should be made to personalize its management. Preventive measures and vaccinations, along with de-escalation of treatment, may help optimize outcomes in this population.
ShibuyaK., MathersC.D., Boschi-PintoC.Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000.BMC Cancer.2002; 2: 37.
3.
RaginC.C., ModugnoF., GollinS.M.The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus.J Dent Res.2007; 86(2): 104–114.
4.
ChenevertJ., ChioseaS.Incidence of human papillomavirus in oropharyngeal squamous cell carcinomas: now and 50 years ago.Hum Pathol.2012; 43(1): 17–22.
LassenP., EriksenJ.G., KrogdahlA.The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial.Radiother Oncol.2011; 100(1): 49–55.
7.
LassenP., PrimdahlH., JohansenJ.Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer.Radiother Oncol.2014; 113(3): 310–316.
8.
O'SullivanB., HuangS.H., Perez-OrdonezB.Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation.Radiother Oncol.2012; 103(1): 49–56.
9.
OvergaardJ., HansenH.S., SpechtL.Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial.Lancet.2003; 362(9388): 933–940.
10.
AngK.K., HarrisJ., WheelerR.Human papillomavirus and survival of patients with oropharyngeal cancer.N Engl J Med.2010; 363(1): 24–35.
11.
O'SullivanB., HuangS.H., SiuL.L.Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis.J Clin Oncol.2013; 31(5): 543–550.
12.
HuangS.H., XuW., WaldronJ.Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas.J Clin Oncol.2015; 33(8): 836–845.
13.
Al-SwiahbJ.N., HuangC.C., FangF.M.Prognostic impact of p16, p53, epidermal growth factor receptor, and human papillomavirus in oropharyngeal cancer in a betel nut-chewing area.Arch Otolaryngol Head Neck Surg.2010; 136(5): 502–508.
14.
LassenP., OvergaardJ., EriksenJ.G.Expression of EGFR and HPV-associated p16 in oropharyngeal carcinoma: correlation and influence on prognosis after radiotherapy in the randomized DAHANCA 5 and 7 trials.Radiother Oncol.2013; 108(3): 489–494.
15.
SheuT., FullerC.D., MendozaT.R.Nomogram for predicting symptom severity during radiation therapy for head and neck cancer.Otolaryngol Head Neck Surg.2014; 151(4): 619–626.
16.
HerreroR., QuintW., HildesheimA.Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica.PLoS One.2013; 8(7): e68329.
17.
TotaJ.E., Chevarie-DavisM., RichardsonL.A.Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies.Prev Med.2011; 53(suppl 1): S12–S21.
18.
KreimerA.R., CliffordG.M., BoyleP.Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review.Cancer Epidemiol Biomarkers Prev.2005; 14(2): 467–475.
19.
St GuilyJ.L., JacquardA.C., PretetJ.L.Human papillomavirus genotype distribution in oropharynx and oral cavity cancer in France–the EDiTH VI study.J Clin Virol.2011; 51(2): 100–104.
20.
ChaturvediA.K., EngelsE.A., PfeifferR.M.Human papillomavirus and rising oropharyngeal cancer incidence in the United States.J Clin Oncol.2011; 29(32): 4294–4301.
21.
GillisonM.L.Human papillomavirus-related diseases: oropharynx cancers and potential implications for adolescent HPV vaccination.J Adolesc Health.2008; 43(4 suppl): S52–S60.
22.
GillisonM.L., BroutianT., PickardR.K.Prevalence of oral HPV infection in the United States, 2009-2010.JAMA.2012; 307(7): 693–703.
23.
SettleK., PosnerM.R., SchumakerL.M.Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients.Cancer Prev Res (Phila).2009; 2(9): 776–781.
24.
D'SouzaG., DempseyA.The role of HPV in head and neck cancer and review of the HPV vaccine.Prev Med.2011; 53(suppl 1): S5–S11.
25.
D'SouzaG., AgrawalY., HalpernJ.Oral sexual behaviors associated with prevalent oral human papillomavirus infection.J Infect Dis.2009; 199(9): 1263–1269.
26.
D'SouzaG., KreimerA.R., ViscidiR.Case-control study of human papillomavirus and oropharyngeal cancer.N Engl J Med.2007; 356(19): 1944–1956.
27.
BegumS., CaoD., GillisonM.Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma.Clin Cancer Res.2005; 11(16): 5694–5699.
28.
ChungC.H., BagheriA., D'SouzaG.Epidemiology of oral human papillomavirus infection.Oral Oncol.2014; 50(5): 364–369.
29.
AngK.K., ZhangQ., RosenthalD.I.Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.J Clin Oncol.2014; 32(27): 2940–2950.
30.
RischinD., YoungR.J., FisherR.Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.J Clin Oncol.2010; 28(27): 4142–4148.
31.
GillisonM.L., ZhangQ., JordanR.Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer.J Clin Oncol.2012; 30(17): 2102–2111.
32.
FakhryC., WestraW.H., LiS.Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.J Natl Cancer Inst.2008; 100(4): 261–269.
33.
PosnerM.R., LorchJ.H., GoloubevaO.Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial.Ann Oncol.2011; 22(5): 1071–1077.
34.
LohausF., LingeA., TinhoferI.HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemo-therapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).Radiother Oncol.2014; 113(3): 317–323.
35.
OvergaardJ., HansenH.S., OvergaardM.A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85.Radiother Oncol.1998; 46(2): 135–146.
36.
RaginC.C., TaioliE.Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis.Int J Cancer.2007; 121(8): 1813–1820.
37.
O'RorkeM.A., EllisonM.V., MurrayL.J.Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis.Oral Oncol.2012; 48(12): 1191–1201.
38.
PignonJ.P., le MaitreA., MaillardE.Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.Radiother Oncol.2009; 92(1): 4–14.
39.
ChenA.M., ZahraT., DalyM.E.Definitive radiation therapy without chemotherapy for human papillomavirus-positive head and neck cancer.Head Neck.2013; 35(11): 1652–1656.
40.
BonnerJ.A., HarariP.M., GiraltJ.Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.N Engl J Med.2006; 354(6): 567–578.
41.
RosenthalD.I., HarariP.M., GiraltJ.Impact of p16 status on the results of the phase III cetuximab (cet)/radiotherapy (RT).J Clin Oncol.2014; 32(5 suppl): 6001.
42.
BaumeisterP., MarteM., ReiterM.EGFR and P-GP expression in oropharyngeal mucosa in relation to smoking.Anticancer Res.2012; 32(5): 1639–1648.
43.
KumarB., CordellK.G., LeeJ.S.EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer.J Clin Oncol.2008; 26(19): 3128–3137.
44.
HongA., DobbinsT., LeeC.S.Relationships between epidermal growth factor receptor expression and human papillomavirus status as markers of prognosis in oropharyngeal cancer.Eur J Cancer.2010; 46(11): 2088–2096.
45.
FarleyJ., SillM.W., BirrerM.Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study.Gynecol Oncol.2011; 121(2): 303–308.
46.
SantinA.D., SillM.W., McMeekinD.S.Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.Gynecol Oncol.2011; 122(3): 495–500.
47.
CheraB.S., AmdurR.J., TepperJ.Phase 2 trial of de-intensified chemoradiation therapy for favorable-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.Int J Radiat Oncol Biol Phys.2015; 93(5): 976–985.
48.
DowthwaiteS.A., FranklinJ.H., PalmaD.A.The role of transoral robotic surgery in the management of oropharyngeal cancer: a review of the literature.ISRN Oncol.2012; 2012: 945162.
49.
SinhaP., LewisJ.S.Jr, PiccirilloJ.F.Extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma.Cancer.2012; 118(14): 3519–3530.
50.
WilliamsR., LeeD.W., ElzeyB.D.Preclinical models of HPV+ and HPV- HNSCC in mice: an immune clearance of HPV+ HNSCC.Head Neck.2009; 31(7): 911–918.
51.
WardM.J., ThirdboroughS.M., MellowsT.Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer.Br J Cancer.2014; 110(2): 489–500.
52.
KenterG.G., WeltersM.J., ValentijnA.R.Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.N Engl J Med.2009; 361(19): 1838–1847.
53.
FormentiS.C., DemariaS.Combining radiotherapy and cancer immunotherapy: a paradigm shift.J Natl Cancer Inst.2013; 105(4): 256–265.
54.
YangW., SongY., LuY.L.Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia.Immunology.2013; 139(4): 513–522.
55.
Lyford-PikeS., PengS., YoungG.D.Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma.Cancer Res.2013; 73(6): 1733–1741.
56.
UkpoO.C., ThorstadW.L., LewisJ.S.Jr. B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma.Head Neck Pathol.2013; 7(2): 113–121.
57.
PetroskyE., BocchiniJ.A.Jr, HaririS.Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices.MMWR Morb Mortal Wkly Rep.2015; 64(11): 300–304.
58.
SoaresG.R., Vieira RdaR., PellizzerE.P.Indications for the HPV vaccine in adolescents: a review of the literature.J Infect Public Health.2015; 8(2): 105–116.
FrakesJ.M., NaghaviA.O., DemetriouS.K.Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer.Cancer.2016; 122(4): 634–641.
